Discarded Blood Tests May Offer Life-Saving Information
|
By LabMedica International staff writers Posted on 08 Sep 2014 |

Image: Scanning electron micrograph of Staphylococcus epidermidis, the commonest coagulase-negative staphylococci found on the skin (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Blood culture isolates are the cornerstone of adequate antibiotic treatment, but many blood cultures are contaminated with bacteria residing on the skin, and the most common contaminants are coagulase-negative staphylococci (CoNS).
Such contaminated cultures are mostly disregarded and discarded but in fact these contaminated cultures contain diagnostic information such as the antibiotic resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated subsequently from the same patient.
Clinical scientists at the Sackler Faculty of Medicine (Tel Aviv, Israel) conducted a retrospective study on patients with positive blood cultures from 2009 to 2012. Data included patient demographics, hospitalization records, comorbidities, blood culture results and date of death. The cohort consisted of 2,518 patients with 5,290 blood cultures, where 1,124 patients had 1,664 blood cultures with CoNS contaminants.
High overall CoNS resistance predicted high overall resistance of the subsequent bacterial isolates for Gram-positive and Gram-negative bacteria. The resistance of CoNS contaminants to a specific antibiotic predicted the resistance of the subsequent bacterial isolates to that antibiotic and highly resistant CoNS isolates were associated with higher short-term mortality.
The team noted that most hospital patients are treated at the outset with broad spectrum antibiotics. Days later, after initial test results are known, clinicians replace broad spectrum antibiotics with more precise narrow-spectrum antibiotics, which treat the specific bacteria identified by the blood sample. Narrow spectrum antibiotics are better for the body because they target specific bacteria as opposed to an entire microenvironment. Moreover, broad spectrum antibiotics might result in altered bacterial environments of the skin and gastro-intestinal tract, promoting inflammation and the emergence of resistant pathogens.
Gideon Y Stein, MD, PhD, a lead author of the study said, “Because we have found a direct correlation between resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated from the same patient, the results of these “junk” samples can be used to predict patient mortality and correct empirical antibiotic therapy. This should serve as an additional, noninvasive, diagnostic tool.” The study was published in the September issue of the Journal of Antimicrobial Chemotherapy.
Related Links:
Tel Aviv University Sackler Faculty of Medicine
Such contaminated cultures are mostly disregarded and discarded but in fact these contaminated cultures contain diagnostic information such as the antibiotic resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated subsequently from the same patient.
Clinical scientists at the Sackler Faculty of Medicine (Tel Aviv, Israel) conducted a retrospective study on patients with positive blood cultures from 2009 to 2012. Data included patient demographics, hospitalization records, comorbidities, blood culture results and date of death. The cohort consisted of 2,518 patients with 5,290 blood cultures, where 1,124 patients had 1,664 blood cultures with CoNS contaminants.
High overall CoNS resistance predicted high overall resistance of the subsequent bacterial isolates for Gram-positive and Gram-negative bacteria. The resistance of CoNS contaminants to a specific antibiotic predicted the resistance of the subsequent bacterial isolates to that antibiotic and highly resistant CoNS isolates were associated with higher short-term mortality.
The team noted that most hospital patients are treated at the outset with broad spectrum antibiotics. Days later, after initial test results are known, clinicians replace broad spectrum antibiotics with more precise narrow-spectrum antibiotics, which treat the specific bacteria identified by the blood sample. Narrow spectrum antibiotics are better for the body because they target specific bacteria as opposed to an entire microenvironment. Moreover, broad spectrum antibiotics might result in altered bacterial environments of the skin and gastro-intestinal tract, promoting inflammation and the emergence of resistant pathogens.
Gideon Y Stein, MD, PhD, a lead author of the study said, “Because we have found a direct correlation between resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated from the same patient, the results of these “junk” samples can be used to predict patient mortality and correct empirical antibiotic therapy. This should serve as an additional, noninvasive, diagnostic tool.” The study was published in the September issue of the Journal of Antimicrobial Chemotherapy.
Related Links:
Tel Aviv University Sackler Faculty of Medicine
Latest Microbiology News
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








